End-of-day quote
Other stock markets
|
||
- USD | - |
07/03 | Earnings Flash (IDXG) INTERPACE BIOSCIENCES Reports Q4 Revenue $10.3M | MT |
07/03 | Interpace Biosciences, Inc. Reports Earnings Results for the Full Year Ended December 31, 2023 | CI |
Sales 2022 | 31.84M 2.66B | Sales 2023 | 40.21M 3.36B | Capitalization | 4.69M 392M |
---|---|---|---|---|---|
Net income 2022 | -22M -1.84B | Net income 2023 | - 0 | EV / Sales 2022 | 0.49 x |
Net Debt 2022 | 11.26M 940M | Net Debt 2023 | 7.69M 642M | EV / Sales 2023 | 0.31 x |
P/E ratio 2022 |
-0.2
x | P/E ratio 2023 |
6.03
x | Employees | - |
Yield 2022 * |
-
| Yield 2023 |
-
| Free-Float | 72.17% |
Managers | Title | Age | Since |
---|---|---|---|
Thomas Burnell
CEO | Chief Executive Officer | 62 | 01/20/01 |
Director of Finance/CFO | 32 | 01/19/01 | |
Nicole Massoll
CTO | Chief Tech/Sci/R&D Officer | - | - |
Members of the board | Title | Age | Since |
---|---|---|---|
Vijay Aggarwal
BRD | Director/Board Member | 75 | 01/22/01 |
Joseph Keegan
BRD | Director/Board Member | 71 | 01/16/01 |
Stephen Sullivan
BRD | Director/Board Member | 77 | 01/04/01 |
1st Jan change | Capi. | |
---|---|---|
-13.48% | 5.69B | |
+4.99% | 1.33B |